Clinical trial NCT02133274: A Psychosocial Intervention Plus Early Palliative Care in the Reduction of Depression of Advanced Cancer Patients
Official title: A Phase II Randomized Controlled Trial to Evaluate a Brief Psychosocial Intervention Together With Early Palliative Care in Reducing Depressive Symptoms of Patients With Advanced Cancer Starting First Line Palliative Chemotherapy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Neoplasms
Keywords: Neoplasms
Early Palliative Care
Psychosocial Intervention
Symptoms
Quality of life
Depression
Lead sponsor: Barretos Cancer Hospital
Sponsor class: OTHER
First posted: 2014-05-08
Enrollment: 63
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine whether a brief psychosocial intervention together with early palliative care are feasible, acceptable and effective in the reduction of depressive symptoms of patients with advanced cancers starting first line palliative chemotherapy.

Detailed description: Patients with advanced cancer report physical, emotional, social and existential problems that may be due to the cancer itself or its treatment. Previous studies have demonstrated the benefit of early inclusion of palliative care (PC) in combination with standard oncologic care in reducing depressive symptoms, improving quality of life, increasing survival and also decreasing unnecessary invasive procedures. However, patients continue to arrive late at PC, even in large comprehensive cancer centers. One of the barriers is the stigma of PC perceived by patients and health professionals as "a place to die." The primaries objectives are to evaluate the feasibility and satisfaction of patients with advanced cancer submitted to a brief psychosocial intervention based on Cognitive Behavioral Therapy (CBT) in addition to early PC and to evaluate the impact of these interventions on the reduction of depressive symptoms. A randomized, open-label, phase II trial, with two intervention arms and a control group. It will be included 150 patients with advanced cancer initiating palliative chemotherapy who meet the selection criteria. Participants will be recruited from the outpatient oncology clinics from the Barretos Cancer Hospital and will be randomized in one of the three treatment arms: arm A, five weekly sessions of brief psychosocial interventions based on CBT in combination with early PC; arm B, early PC only; arm C, standard oncologic care. The Hospital Anxiety and Depression Scale (HADS), Patient Health Questionnaire-9 (PHQ-9), Brazilian version of the Edmonton Symptom Assessment System (ESAS-br), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 PAL (EORTC QLQ-C15-Pal), 13-item measure of patient satisfaction (FAMCARE-P13), and the Disease Understanding Protocol, will be the instruments used for data collection. Patients will answer these instruments at baseline and after 45, 90, 120, and 180 days after randomization. An interim analysis is planned to occur after the inclusion of 20 participants with complete data in each arm; if the Cohen's effect size between the arms A and B is small (d\<\<0.2), the study will continue only with arms B and C.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years and \<75 years;
* Adequate knowledge about the cancer diagnosis;
* Starting first line palliative antineoplastic treatment;
* Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≤ 2;
* Life expectancy\> 6 months and \<24 months (as per the medical oncologist);
* Must have on the following diagnoses:

Metastatic or unresectable recurrent breast cancer; Stage IIIC or IV recurrent platinum-resistant ovarian cancer; Metastatic or unresectable recurrent cervix cancer; Metastatic or unresectable recurrent endometrial cancer; Metastatic or unresectable recurrent head and neck cancer (after previous radiotherapy); Hormone-refractory metastatic or unresectable recurrent prostate cancer; Metastatic or unresectable recurrent genitourinary cancer; Metastatic or unresectable recurrent non-small cell lung cancer; Extensive-stage or recurrent small cell lung cancer; Metastatic or unresectable recurrent gastrointestinal cancer;

Exclusion Criteria:

* Currently undergoing any psychological treatment due to a psychological disorder;
* Currently using antidepressants to treat depressive disorders and / or anxiety;
* Any cognitive deficit or attention problem that could interfere in the ability to answer questionnaires or understand the study aims (as per investigator);
* Current or previous established diagnosis of any of the following psychological conditions: Substance-Related Disorders; Schizophrenia and Other Psychotic Disorders; Mood Disorders (Depressive Disorders, Bipolar Disorders); Anxiety Disorders; Dissociative Disorders; Personality Disorders; and / or a history of suicide attempt;
* Patients with single resected metastasis;
* Any co-morbid condition, which, in the opinion of the investigator, could interfere with the safety, the compliance with the study or with the interpretation of the results.
* Patients unable to go to the hospital for the study visits, regardless of the reason.

Primary outcomes:
measure: Change from baseline in depression symptoms on the HADS-D and PHQ-9 at day 90.
timeFrame: Baseline, Day 90.
measure: Change from baseline in satisfaction with care on the FAMCARE-patient scale at days Days 45, 90, 120 and 180.
timeFrame: Baseline, Days 45, 90, 120 and 180.
measure: Descriptive results about feasibility of the study.
timeFrame: Average duration in minutes of each intervention session (both regarding Palliative Care consultation and Psychological session); number of non-attendance to the interventions (absences); reasons reported by patients for missing.
Secondary outcomes:
measure: Change from baseline in depressive symptoms on the HADS-D and PHQ-9 at days 45,120 and 180.
timeFrame: Baseline, Days 45, 120, 180.
measure: Change from baseline in anxiety symptoms on the HADS-A at days 45,90, 120 and 180.
timeFrame: Baseline, Days 45, 90, 120, 180.
measure: Proportion of patients answering that their cancer is curable as measured using an adapted instrument to evaluate Cancer Understanding.
timeFrame: At 90, 120 and 180 days.
measure: Change from baseline in cancer symptoms on the ESAS at days 45,90, 120 and 180.
timeFrame: Baseline, Days 45, 90, 120, 180.
measure: Change from baseline in quality of life on the EORTC QLQ-C15-Pal at days 45,90, 120 and 180.
timeFrame: Baseline, Days 45, 90, 120, 180.
Other outcomes:
Locations:
city: Barretos
country: Brazil
facility: Barretos Cancer Hospital
state: São Paulo
Study officials:
affiliation: Barretos Cancer Hospital
name: Carlos E Paiva, MD, PHD
role: PRINCIPAL_INVESTIGATOR
References:
citation: do Carmo TM, Paiva BSR, de Oliveira CZ, Nascimento MSA, Paiva CE. The feasibility and benefit of a brief psychosocial intervention in addition to early palliative care in patients with advanced cancer to reduce depressive symptoms: a pilot randomized controlled clinical trial. BMC Cancer. 2017 Aug 23;17(1):564. doi: 10.1186/s12885-017-3560-6.
citation: do Carmo TM, Paiva BS, de Siqueira MR, da Rosa Lde T, de Oliveira CZ, Nascimento MS, Paiva CE. A phase II study in advanced cancer patients to evaluate the early transition to palliative care (the PREPArE trial): protocol study for a randomized controlled trial. Trials. 2015 Apr 12;16:160. doi: 10.1186/s13063-015-0655-8.